C4 Therapeutics (CCCC) Equity Ratio (2019 - 2026)

C4 Therapeutics has reported Equity Ratio for 8 years, with the latest figure at 0.71 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 16.63% year-over-year to 0.71; the trailing twelve-month figure through Mar 2026 stood at 0.71 (up 16.63% YoY), and the FY2025 full-year result was 0.71, up 15.66% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.71, roughly flat from 0.71 in the prior quarter.
• The five-year high for Equity Ratio was 0.71 in Q4 2025, with the low at 0.58 in Q3 2025.
• Average Equity Ratio over 5 years is 0.65, with a median of 0.65 recorded in 2023.
• Year-over-year, Equity Ratio dropped 12.68% in 2022 and grew 16.63% in 2026.
• Tracing CCCC's Equity Ratio over 5 years: stood at 0.67 in 2022, then fell by 2.61% to 0.65 in 2023, then decreased by 5.5% to 0.62 in 2024, then climbed by 15.66% to 0.71 in 2025, then dropped by 0.32% to 0.71 in 2026.
• The last three Equity Ratio figures came in at 0.71 (Q1 2026), 0.71 (Q4 2025), and 0.58 (Q3 2025), per Business Quant data.

Peer Comparison